Anti-platelet agregation: what did we learn from the evidence?

Authors

  • Augusto Lavalle Cobo Finochietto Sanatorium, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v56i3Sup.552

Keywords:

anti-platelet agregation, treatment

Abstract

Hyperglycemia and insulin resistance, characteristics of patients with type 2 diabetes mellitus (T2D), produce platelet and endothelial alterations, increasing the risk of thrombotic events. The efficacy and benefit of antiplatelet therapy are well established in patients with atherosclerotic cardiovascular disease. There is little discussion about the combination of low doses of acetylsalicylic acid (ASA) and a P2Y12 receptor inhibitor in the acute setting of a cardiovascular event. Current evidence seeks to answer the question of how long to maintain this double regimen, mainly in patients with a high risk of bleeding. Maintaining dual antiplatelet therapy for at least one year is recommended after an acute event.This time could be shortened for patients with high bleeding risk and extended for a longer period in patients with a high thrombotic risk. In this scenario, rivaroxaban 2.5 mg b.i.d, can be considered.

Author Biography

Augusto Lavalle Cobo, Finochietto Sanatorium, Autonomous City of Buenos Aires, Argentina

Specialist in Cardiology; Coordinator of the Cardiology Service

References

I. Santilli, F, Simeone, P, Liani, R. The role of platelets in diabetes mellitus. In: Michelson, AD (ed.) Platelets. Amsterdam: Elsevier, 2019, pp. 469–503

II. Lawton J, Tamis-Holland J, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary. J Am Coll Cardiol 2022 Jan;79(2):197-215.

III. Masson W, Barbagelata L, Lavalle-Cobo A, Lobo M, Masson G, Nogueira JP, Vergès B. Low-doses aspirin in the primary prevention of cardiovascular disease in patients with diabetes: Meta-analysis stratified by baseline cardiovascular risk. Diabetes Metab Syndr 2022 Jan;16(1):102391.

IV. Cainzos-Achirica M, Miedema MD, McEvoy JW, et al. Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). Circulation 2020 May 12;141(19):1541-1553.

Downloads

Published

2022-09-01

How to Cite

Lavalle Cobo, A. (2022). Anti-platelet agregation: what did we learn from the evidence?. Journal of the Argentine Society of Diabetes, 56(3Sup), 55–55. https://doi.org/10.47196/diab.v56i3Sup.552

Issue

Vol. 56 No. 3Sup (2022): September/December 2022

Section

6 voices in 10 minutes part 1

License

Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.

 

Most read articles by the same author(s)